Clinical trial

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-08-01

PhasePHASE2

Study timeline

Study start (unknown)2007-08-01Date precision: month

Registry last updated2013-04-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancer (NSCLC)unresolved

Interventions

ABT-869 .25 mg/kgDRUG

ABT-869 0.10 mg/kgDRUG

Sponsors & collaborators

AbbVie (prior sponsor, Abbott)lead sponsor

Genentech, Inc.collaborator

Mapped research locations

SingaporeSingapore2 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 St LouisMissouri, United States1 IndianapolisIndiana, United States1 AuroraColorado, United States1 TaipeiTaiwan1 CharlotteNorth Carolina, United States1 SacramentoCalifornia, United States1 ToulouseFrance1 MarseilleFrance1 MemphisTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00517790 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.